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ABSTRACT
Politicians and public health ofﬁcials have joined specialist professionals in recognising antibiotic
resistance as a threat to modern medicine. Their response has centred on minimising unnecessary
antibiotic prescribing, aiming to reduce selection pressure for resistance. Despite a few hopeful trends
(e.g., declining penicillin resistance among pneumococci in the UK), established resistance is proving
hard to displace; moreover, new resistances continue to emerge and to proliferate at new sites. There
consequently remains a strong need for new antibiotics, particularly those directed against multiresist-
ant Gram-negative bacteria in hospitals. Already some nonfermenters of the genera Acinetobacter and
Pseudomonas are resistant to all good antibiotics and many Enterobacteriaceae are resistant to all except
carbapenems. There is also a growing need for new agents against community-acquired pathogens,
including the agents of tuberculosis, gonorrhoea and urinary tract infections. Unless antibacterial
development is re-energised, there is a serious risk that a growing proportion of infections, especially in
hospitals, will become effectively untreatable.
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INTRODUCTION
Antibiotics have revolutionised medicine, allow-
ing treatment of infections that were once widely
fatal and safeguarding procedures that were once
unthinkable. Their availability has created an
assurance of health unknown to previous gener-
ations. This assurance, now taken for granted, will
be dissipated if resistance development continues
to outstrip antibiotic development, as in the past
decade.
Selection of resistance is an inevitable, Darwin-
ian consequence of antibiotic usage, though its
frequency varies with: (i) the regimens and extent
of use, (ii) the effectiveness of infection control,
and (iii) random factors, such as the initial escape
of resistance genes to mobile DNA and into
biologically ‘ﬁt’ strains. No antibiotic escapes all
resistance and, if one did so, its likely effect would
be to shift the microbial ecology in favour of more
resilient opportunist pathogens, able to exploit
the vacated niche.
Concern about resistance has escalated in the
past 5–6 years, with reports by, amongst others,
the British House of Lords [1], UK Department of
Health [2], European Commission [3], World
Health Organization [4] and an inter-agency force
in the USA [5]. These reports all argue for reduced
antibiotic use, for better-tailored use (i.e., appro-
priate drug, dose and duration), and for better
infection control. Perhaps because of these
reports, along with subsequent press coverage
and governmental advertising, community use of
antibiotics in the UK has fallen c. 23% since 1997
[6], with a greater reduction in prescribing to
children. Meanwhile, antimicrobial prescriptions
to ambulatory patients in the USA have declined
over 20% [7] and the use of antibiotics as growth
promoters in animal husbandry has been banned
in the EU. Some improvements in resistance
trends have followed these reductions, though
causality is hard to prove. Penicillin nonsuscep-
tibility among pneumococci is declining in pre-
valence in the UK (Fig. 1) and, following the ban
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on growth promotors, there has been a decline in
several resistances, including to vancomycin,
among enterococci from poultry and pigs in
Denmark [8]. Vancomycin resistance in clinical
enterococci in England and Wales is falling too,
from a peak of nearly 30% in 1999 to 17% in 2002.
These, though, are isolated successes and, as a
whole, resistance has continued to accumulate in
the past 5–6 years with critical new types con-
tinuing to emerge, as with vancomycin-resistant
Staphylococcus aureus, or to increase in prevalence
and geographic range, as with carbapenemases in
nonfermenters, ciproﬂoxacin-resistant gonococci
and CTX-M b-lactamases.
Before reviewing particular concerns, it should
be said that there are sound reasons to doubt
whether reductions in antibiotic use can be
achieved or maintained at a sufﬁcient degree to
substantially reverse growing resistance. Cessa-
tion of use, as with growth promoters, is not an
option for therapeutic drugs, and the objectives
of reducing usage and selection pressure are
counter-poised by social and economic factors,
including (i) ageing populations, with a growing
body of vulnerable patients who migrate between
hospitals and nursing homes, re-circulating resist-
ant strains [9,10]; (ii) advances elsewhere in
medicine, which enlarge the pool of immunosup-
pressed and vulnerable patients; (iii) globalisation
of peoples and produce, spreading resistance
among countries, as with the introduction of
penicillin-resistant pneumococci to Iceland by
returning holiday-makers and their subsequent
spread in socialised childcare [11]; and (iv) by
stressed healthcare systems, where patient
throughput receives highest priority. What is
more, a growing body of data shows that many
resistant bacteria are biologically ﬁt or, if not
immediately so, undergo compensatory muta-
tions that offset the ﬁtness cost of resistance,
meaning that they are difﬁcult to displace.
Against this background it is naı¨ve to anticipate
that small improvements or reductions in anti-
biotic use can hugely turn the tide of resistance
[12,13].
It follows that antibiotic development remains
vital if man is to keep ahead of resistance, and it is
partly reassuring that, despite press hype, some
new agents do continue to be developed (Table 1).
The word ‘partly’ is used because it is not clear
where the next antibiotics will come from, and
because of a mismatch between what is needed
and what is developed.
0
1
2
3
4
5
6
89 90 91 92 93 94 95 96 97 98 99 00 01 02
%
 
n
o
n
-s
u
sc
ep
tib
le
0
1
2
3
4
5
6
7
8
99 00 01 02 03
%
 
n
o
n
-
su
sc
ep
tib
le
(a)
(b)
Fig. 1. Prevalence of penicillin nonsusceptibility in inva-
sive S. pneumoniae based (a) on reports to the Health
Protection Agency for most laboratories in England and
Wales and (b) on sentinel surveillance of 23 UK hospitals
under the European Antimicrobial Resistance Surveillance
System (http//:http://www.earss.rivm.nl). Both studies
conﬁrm falling resistance.
Table 1. Spectra of antibiotics recently launched, or anti-
cipated by 2008
Gram-positive
cocci only
Respiratory
pathogens
Broad
spectrum
Quinupristin ⁄
dalfopristin
(not E. faecalis)
Telithromycin Ertapenemc
Linezolid Peptide
deformylase
inhibitors
Doripenemc
Daptomycin Moxiﬂoxacinb Tigecycline
Oritavancin Garenoxacinb Sitaﬂoxacin
Dalbavancin
(not Van A VRE)
Gemiﬂoxacinb
Anti-MRSA
cephalosporinsa
aHave broad-spectrum activity but tailored vs. MRSA.
bHave broad-spectrum activity but tailored vs. S. pneumo-
niae and no better than ciproﬂoxacin vs. Gram-negative
bacteria.
cNot active against strains resistant to existing carbapen-
ems.
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NEED FOR NEW ANTIBIOTIC VERSUS
NOSOCOMIAL INFECTIONS
The need for new agents is most pressing in
hospital infections, where small but growing
numbers of isolates, mostly Gram-negative non-
fermenters of the genera Acinetobacter and Pseudo-
monas, are resistant to all ‘good’ antibiotics and
where growing numbers of Enterobacteriaceae
are resistant to all except carbapenems. Whilst
there is a lesser shortage of agents active against
staphylococci, the prevalence of infections with
methicillin-resistant Staphylococcus aureus (MRSA)
remains extremely high in many countries.
Acinetobacter and Pseudomonas spp.
These genera account for 10% of in-patient
infections (Table 2), but for a higher proportion
in, for example, intensive care and burns units.
P. aeruginosa is also important as a pulmonary
pathogen in cystic ﬁbrosis. Along with rarer
nonfermenters these species account for most of
the cases where we, as a national reference
laboratory, encounter strains resistant to all ‘good’
antibiotics. Acinetobacter spp. (principally Acineto-
bacter baumannii) are notorious for their capacity
to accumulate resistance, and for their tenacity.
They frequently cause clonal outbreaks, which
can be extremely difﬁcult to terminate, even with
cohorting of patients, sterilisation of equipment,
reinforcement of handwashing, and deep-clean-
ing of facilities. Throughout the 1980s and 1990s
A. baumannii became progressively more-often
resistant to cephalosporins and ﬂuoroquinolones,
having previously become widely resistant to
penicillins and aminoglycosides [15]. By the mid-
1990s, carbapenems were the treatment mainstay
and no longer the reserve.
Now, carbapenem resistance is increasing
steadily, variously mediated by acquired VIM
and IMP metallo-b-lactamases, OXA carbapene-
mases and combinations of weak, poorly charac-
terised carbapenemases, together with reduced
drug accumulation [16]. This increase is illustra-
ted for the USA in Fig. 2, but the position is worse
in South America and in the Far East [17] whilst,
in South-east England, three carbapenem-resist-
ant strains, each with subvariants, are circulating
in up to 50 hospitals each, with these numbers
growing steadily [18]. The most prevalent of these
latter strains has an unknown mechanism of
carbapenem resistance; the others have OXA-23
enzyme.
Some carbapenem-resistant acinetobacters
remain susceptible to sulbactam, or to one or
more aminoglycosides, but these sensitivities are
not universal and aminoglycoside-modifying
enzymes are frequent, notoriously including
APH(3¢)-VI, which affects amikacin and isepami-
cin – otherwise the most enzyme-resistant ana-
logues [19]. Most isolates, including those
Table 2. Relative prevalence of major pathogens among
in-patient infections and in bacteraemias
Organism All in-patient
isolates,UK &
Ireland, 2001 (%)
Bacteraemias
2001,England &
Wales (%)
E. coli 18.3 21.1
Klebsiella spp. 4.4 5.7
P. mirabilis 3.1 3.3
AmpC-inducible
Enterobacteriaceaea
6.9 3.3
P. aeruginosa 10.0 3.2
Acinetobacter spp. 1.1 0.8
Methicillin-
susceptible S. aureus
18.4 13.1
MRSA 14.8 9.9
Coagulase-ve
staphylococci
6.6 10.7
S. pneumoniae 2.2 6.7
a- and nonhaemolytic
streptococci
0.9 3.5
b-Haemolytic
streptococci
4.8 3.0
Enterococci 4.8 7.1
Others 3.6 8.6
aIncludes Enterobacter spp., Citrobacter spp., Morganella
morganii and Serratia spp.
Data: Health Protection Agency and Livermore et al. [14]
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Fig. 2. Rising carbapenem resistance (black) or intermedi-
ate resistance (grey) among Acinetobacter spp. isolates at
250 US hospitals, as reported to the TSN-Databases.
Resistances to other agents are already hugely frequent in
the genus. Reproduced with permission from Livermore
[21].
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resistant to carbapenems, remain susceptible to
polymyxins B and E (colistin), but these are,
rather, nephrotoxic compounds with poor efﬁcacy
in the case of pneumonias – a common infection
site [20,21]. Minocycline, too, is widely active, but
would not ordinarily be considered appropriate
in the case of severe infections.
P. aeruginosa is a more frequent pathogen than
A. baumannii, accounting for 10% of in-patient
isolates and 3.2% of all bacteraemias in the UK
[Table 2]. Resistance is less frequent than in
Acinetobacter spp. and, based on US data, rates
to b-lactams and aminoglycosides remain around
5–15% with only ﬂuoroquinolone resistance ris-
ing steadily [22]. These ﬁgures, however, disguise
much higher resistance rates in many burns,
intensive care, and cystic ﬁbrosis units and deeper
analysis (Fig. 3)2 shows rising proportions of
isolates multi-resistant to two to ﬁve of six index
antibiotics [23].
Multi-resistance in P. aeruginosa can reﬂect the
accumulation of successive mutations that dere-
presschromosomalb-lactamase,up-regulatemulti-
drug efﬂux, reduce permeability and diminish
topoisomerase sensitivity to quinolones [23]. This
accumulationmay be accelerated by co-selection of
hypermutability with a ﬁrst resistance, especially
in cystic ﬁbrosis patients [24]. Alternatively,
multiresistance can reﬂect the acquisition of
plasmids or integrons encoding combinations
of b-lactamase and aminoglycoside-modifying
enzymes [23]. Several integrons (natural genetic
recombination systems) can encode IMP, VIM or
SPM metallo-b-lactamases together with AAC[6¢]
aminoglycoside acetyltransferases, conferring
resistance to all aminoglycosides and b-lactams,
except sometimes, aztreonam. Such strains –
many of them independently resistant to ﬂuoro-
quinolones – have been reported in Japan since
the late 1980s and, since 1997, from a growing list
of countries in Asia, Europe and the Americas
[21]. Major outbreaks of producers have occurred
in Greece, Korea, Hong Kong, Brazil and Colom-
bia [25,26], some lasting months or years, others
with the strain(s) spreading among multiple
hospitals. Most multiresistant P. aeruginosa
remain susceptible to polymyxins, but, as with
Acinetobacter infections, efﬁcacy is uncertain,
especially in pneumonias [20].
Among the compounds listed in Table 1, sita-
ﬂoxacin is slightly more active than ciproﬂoxacin
against ﬂuoroquinolone-susceptible A. baumannii
strains, but none of the ﬂuoroquinolones is
superior to ciproﬂoxacin against P. aeruginosa
and none is reliably active against Acinetobacter
strains with high-level ciproﬂoxacin resistance.
Tigecycline, the novel tetracycline [Table 1], is
active against A. baumannii but, as with minocy-
cline, there is a need to establish clinical efﬁcacy
in severe infection; it is not active against
P. aeruginosa.
In short, nonfermenters account for about 10%
of in-patient infections, though for a smaller
proportion of bacteraemias. They are becoming
more resistant, and more-often resistant to all
good drugs. Few of the new agents listed in
Table 1 show promise against Acinetobacter spp.;
none does so against P. aeruginosa. It is here
that we are closest to the much-feared ‘end of
antibiotics’.
Enterobacteriaceae
Pan-resistance remains extremely rare in nosoco-
mial Enterobacteriaceae, because carbapenems
retain near-universal activity [21]. Resistance to
other agents is rising steadily, however, and two
trends must be particularly highlighted.
First, the utility of the ﬂuoroquinolones is
eroding. This is illustrated, for England and
Wales, in Fig. 4, which shows rising ciproﬂoxacin
resistance trends in Klebsiella and Enterobacter
bacteraemias (mostly hospital-acquired) as well
as E. coli bacteraemias (variously hospital- and
community-acquired) [27]. Karlowsky et al. [28]
have reported similar results in the USA, with
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Fig. 3. Proportion of P. aeruginosa isolates resistant to 1–6
agents among ceftazidime, piperacillin, imipenem, amika-
cin, gentamicin and ciproﬂoxacin among those reported
from >250 laboratories to the TSN-Databases. Note the
growing proportions resistant to two to ﬁve of these core
antipseudomonal agents. Reproduced with permission
from Livermore [23].
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ciproﬂoxacin and levoﬂoxacin resistance rates
rising from 6 to 11% between 1998 and 2001.
Whilst these rises are signiﬁcant, the prevalence
rates remain low compared to Far East, India and
South America.
Second, the proportion of Enterobacteriaceae
resistant to third-generation cephalosporins con-
tinues to grow. Such resistance often arises
through mutational hyper-production of chro-
mosomal AmpC b-lactamases in Enterobacter
spp., Citrobacter freundii, Morganella morganii,
Serratia and Providencia spp. This mechanism
and its contingent resistance is seen in 30–40%
of Enterobacter spp. isolates worldwide, with
local rates up to 70%. Even if a strain is
susceptible at ﬁrst isolation there is a substantial
risk (c. 20% in a bacteraemia) that derepressed
mutants will be selected in cephalosporin ther-
apy, meaning that these drugs cannot be per-
ceived as reliable in infections caused by these
species [29,30]. Cephalosporin resistance also can
arise via acquisition of plasmids encoding
‘extended-spectrum b-lactamases’ (ESBLs). Until
recently, most ESBLs outside South America
were mutants of the classical TEM and SHV
b-lactamases that have long been a source of
resistance to penicillins in Enterobacteriaceae.
Such mutant enzymes are most prevalent in
nosocomial Klebsiella spp., occurring in c. 25% of
intensive care isolates of this genus in Europe
[31] and a few ESBL-producing strains of
K. pneumoniae and Enterobacter aerogenes have
achieved epidemic spread among hospitals
[32,33]. Many ESBL producers, including these
epidemic strains, are multiresistant also to ﬂuoro-
quinolones and aminoglycosides.
ESBLs are more prevalent in South America
than elsewhere [34] (Fig. 5) and the types are
different, too at least in the southern ‘cone’ of
the continent, where ‘CTX-M’ enzymes predom-
inate [35,36]. CTX-M enzymes are not TEM or
SHV mutants but, rather, have evolved by the
escape and genetic modiﬁcation of the chromo-
somal b-lactamases of Kluyvera spp. In the past
5 years, CTX-M enzymes have also begun to
spread widely in Europe (especially Eastern
Europe), Asia and North America. In parts of
Europe, China and Russia they are overtaking
TEM and SHV-related ESBLs in prevalence and,
in the UK, are spreading dramatically into
community Escherichia coli (see below).
The result of rising quinolone and cephalo-
sporin resistance is to drive carbapenem use.
Thus far, even 19 years after imipenem’s launch,
these agents retain near-universal activity
against nosocomial Enterobacteriaceae [21] with
resistance only arising when a potent carbapen-
emase is present in a remarkably impermeable
strain. It is uncertain if this assurance will last
once carbapenems are used more heavily – as
they will be with the erosion of cephalosporin
and quinolone activity. If the carbapenem activ-
ity were lost, many infections would become
effectively untreatable. Among the noncarb-
apenems listed in Table 1, only the ﬂuoroqui-
nolones and tigecycline are active against
Enterobacteriaceae, and the best new quinolone
(sitaﬂoxacin) has only marginal activity against
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Fig. 4. Growing proportions of E. coli (black) Klebsiella spp.
(grey) and Enterobacter spp. (white) resistant to ciproﬂoxa-
cin. Based on reports to the Health Protection Agency for
bacteraemias from most clinical laboratories in England
and Wales (updated from Ref. 27).
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Fig. 5. Proportions of Klebsiella spp., E. coli and Proteus
mirabilis with ESBLs, based on data reported under the
SENTRY surveillance [34]. Note that high rate of ESBLs in
Latin America, perhaps reﬂecting the early dissemination
of CTX-M enzymes in this region. These enzymes are now
spreading worldwide.
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isolates resistant to ciproﬂoxacin. Tigecycline is
almost universally active against Enterobacteri-
aceae except Proteeae (which are resistant to all
tetracyclines), but it will require a major shift in
practice to accept a tetracycline for use in the
case of severe nosocomial infections.
Nosocomial Gram-positive bacteria
Methicillin-resistant Staphylococcus aureus (MRSA)
are the single most important hospital pathogens
in many countries. In the UK, they account for
15% of all clinically signiﬁcant in-patient isolates
and 10% of bacteraemias (Table 2) and, whilst
their prevalence remains low in Scandinavia and
the Netherlands (1–2%), it is high or rising
elsewhere (Fig. 6) placing a major burden on
healthcare systems [37]. MRSA evolve rarely and
their epidemiology reﬂects the spread of a few
strains among many patients; in the UK, just two
strains account for 95% of MRSA bacteraemias
[38].
There is now little shortage of drugs active
against MRSA. Vancomycin, teicoplanin, qui-
nupristin ⁄dalfopristin, linezolid and daptomycin
have nearly universal in vitro activity, as do the
developmental agents tigecycline, oritavancin and
dalbavancin. In addition, many MRSA remain
susceptible to fusidic acid, minocycline, trimeth-
oprim and rifampicin, which may be used in
combination. A growing proportion of MRSA
isolates, in several European countries, are regain-
ing susceptibility to gentamicin. The problem
with MRSA is not resistance per se, but tenacity
and the fact that vancomycin, still the standard
therapy, is poorly effective. Newer agents (nota-
bly linezolid) may be superior in some settings
[39] but this remains to be established more
widely. Thus far, too, there is little evidence to
suggest that they can ‘beat’ the MRSA problem in
the way that methicillin ‘beat’ penicillin-resistant
staphylococcus in the 1960s. b-Lactams are super-
ior to vancomycin against methicillin-susceptible
S. aureus, giving the implication that, if analogues
active against MRSA could be developed, these
might have great potential. Two such agents,
RWJ-54428 (Johnson & Johnson, Raritan, NJ, USA)3
[40] and BAL 9141 (Basilea, Basel, Switzerland)4
[41], are presently in clinical development, but the
area is difﬁcult, with many previous anti-MRSA
b-lactams having been abandoned.
The need for new anti-enterococcal agents is
less acute, not only because many of the com-
pounds listed in Table 1 are active but also
because fewer patients are infected than with
MRSA. Nevertheless enterococcal endocarditis
remains a problem when it is caused by a
vancomycin-resistant strain that also has high-
level resistance to aminoglycosides and either (i)
the organism is Enterococcus faecium, which is
inherently resistant to ampicillin or (ii) the patient
is allergic to ampicillin. Treatment is considered
to require bactericidal activity and, among the
agents in Table 1, only daptomycin and oritavan-
cin meet this criterion, with their clinical efﬁcacy
in the setting still to be established.
NEED FOR NEW ANTIBIOTICS IN THE
COMMUNITY
There is a much clearer association between
species and infection type in community-acquired
infection than in hospitals, where opportunists
can attack many sites in vulnerable patients.
Consequently, it is better to organise this section
by indication than by organism.
Respiratory infections account for over half of
all community antibiotic prescribing, much of it
inappropriate. The size of this market explains
why many of the developmental antibiotics
listed in Table 1 are tailored against respiratory
infections but, whatever the commercial logic,
the medical need for new agents is much less
here than in the context of nosocomial infection.
Amongst the major pathogens, H. inﬂuenzae and
M. catarrhalis remain almost universally suscept-
ible to oral third-generation cephalosporins and
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Fig. 6. MRSA as a percentage of S. aureus bacteraemias in
countries with extensive reporting (>250 S. aureus bacter-
aemias in ‡3 of 4 years) to the European Antimicrobial
Resistance Surveillance System (http://www.earss.
rivm.nl). Despite high proﬁle and the availability of anti-
MRSA agents there is no evidence of reducing prevalence.
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ﬂuoroquinolones, and although there is concern
about resistance in S. pneumoniae, this seems to
be much scarcer when clinical trails seek to
recruit consecutive patients than in laboratory
surveys. In any event, increasing deployment
of vaccination targeted against the serotpyes
where resistance is most frequent, looks set to
impact on the incidence of severe pneumococcal
infection.
The community-acquired respiratory infection
for which there is a need for new agents is
tuberculosis, where resistance continues to in-
crease in many developing countries [42], especi-
ally those where the public health infrastructure
has crumbled. With increasing human migration,
these resistant strains are likely to be increasingly
imported into developed countries.
In the case of urinary infections (the second
commonest reason for community prescribing of
antibiotics) there is frequent resistance to ampi-
cillin and trimethoprim in E. coli and, in many
parts of the world, rising resistance to ﬂuoroqu-
inolones. More disturbingly CTX-M b-lactamases
are achieving greater penetration into commu-
nity isolates than did earlier ESBLs. Many UK
counties are presently seeing urinary infections
with CTX-M-15-producing E. coli resistant to
penicillins, cephalosporins, quinolones and trim-
ethoprim, mostly among patients with some
recent hospital contact. The oral treatment
options narrow to nitrofurantoin, which cannot
be used empirically as it is not active against
Proteeae, and fosfomycin, where mutational
resistance can readily emerge. The alternative is
to admit the patient and administer a carbape-
nem, adding cost and complexity [43].
Gonorrhoea is perhaps a surprising inclusion
on a list of infections where new drugs are
needed. Nevertheless, it is an infection where
sudden shifts in resistance occur, owing to rapid
dissemination of resistant strains by treatment
failures. The 1970s saw a dramatic spread of
b-lactamase-producing strains in the Far East,
and, similarly, the present decade is seeing
escalating resistance to ﬂuoroquinolones [44].
For example, the UK had only rare, largely
imported, cases of ciproﬂoxacin-resistant gonor-
rhoea until 2001; by 2002, however, there was
domestic transmission of resistant clones and a
rise in the prevalence of resistance to over 10%,
compared with 2–3% in 2000–1 [44,45]. Only
the third-generation cephalosporins or spectino-
mycin now meet the objective of achieving a
95% cure rate.
CONCLUSION
Even with more appropriate prescribing, it seems
likely that antibacterial resistance will continue to
accumulate in many pathogens and settings,
especially in hospitals. Clinicians already see
pan-resistance to ‘good’ antibiotics in isolates of
P. aeruginosa and Acinetobacter spp., and the
absence of pan-resistance in Enterobacteriaceae
is only due to the continued efﬁcacy of the
carbapenems. If carbapenemases do spread
widely we will face a situation where many
nosocomial Gram-negative infections become
effectively untreatable. It is here, against Gram-
negative opportunists, that the medical need for
new agents is most acute and where, apart from
tigecycline, there are few new agents in advanced
development. And, whilst new treatments are
becoming available for infections caused by
multiresistant Gram-positive pathogens, the goal
of ﬁnding a drug that is as effective, against
MRSA, as penicillin was against staphylococci in
the 1940s remains elusive. In the community,
multiresistance is complicating the treatment of
urinary tract infections, gonorrhoea and tubercu-
losis, though problems with S. pneumoniae may
have been over-stated.
The medical need for new antibiotics is clear.
What is less clear is the commercial logic. The
proportion of infections that cannot be treatedwith
present agents is small, restricting demand, and
the infections are widely scattered, complicating
clinical trials. As other articles in this supplement
will show, many of the largest pharmaceutical
companies have concluded that drugs directed
against chronic diseases offer a better revenue
stream than antibacterial agents, where the courses
are short and restriction is likely. Several major
houses have abandoned antibacterial development
and others have merged, leaving one developer
where there previously were two or more. Some
small pharma and biotech companies do seek to
develop antibiotics but most depend on venture
capital not sales income and, with the present
regulatory burden, face huge barriers to market
entry. These barriers were raised with the best
intentions of ensuring public safety but will have
the opposite effect if they stave off antibiotic devel-
opment whilst resistance continues to accumulate.
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